Vivos Therapeutics (NASDAQ:VVOS) & TELA Bio (NASDAQ:TELA) Head-To-Head Survey

TELA Bio (NASDAQ:TELA) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares TELA Bio and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TELA Bio	-79.83%	-201.62%	-58.60%
Vivos Therapeutics	-98.42%	-665.17%	-122.48%

Volatility and Risk

TELA Bio has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.94, indicating that its share price is 694% more volatile than the S&P 500.

Valuation and Earnings

This table compares TELA Bio and Vivos Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$58.45 million	2.18	-$46.66 million	($2.07)	-2.50
Vivos Therapeutics	$13.80 million	0.53	-$13.58 million	($11.05)	-0.24

Vivos Therapeutics has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

94.3% of TELA Bio shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 5.7% of TELA Bio shares are held by insiders. Comparatively, 9.6% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for TELA Bio and Vivos Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	0	0	3	0	3.00
Vivos Therapeutics	0	0	0	0	N/A

TELA Bio presently has a consensus target price of $13.67, suggesting a potential upside of 164.35%. Given TELA Bio’s higher possible upside, equities analysts clearly believe TELA Bio is more favorable than Vivos Therapeutics.

Summary

TELA Bio beats Vivos Therapeutics on 9 of the 13 factors compared between the two stocks.

About TELA Bio

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.